Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.


Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

Prostate Cancer Brachytherapy Outcomes Linked to PSADT

PSA doubling time (PSADT) can predict oncologic and survival outcomes among men who receive brachytherapy for localized prostate cancer (PCa), new study findings suggest. Results showed that shorter PSADT is associated with worse disease-specific, metastasis-free, and overall survival.

Read more.

source: Renal and Urology News